Bionomics: Analysis of Full Results from PREVAIL Phase 2 Study of BNC210 in Social Anxiety Disorder (SAD)
|DATE:||March 9, 2023|
|TIME:||8:00 AM EST|
About The Event
Join us for the Bionomics webcast discussing the full results from the PREVAIL Phase 2 study of BNC210 in Social Anxiety Disorder (SAD). The company will discuss how the PREVAIL study achieved its goals, constituted a proof of concept in SAD, and provided valuable information for designing the late-stage BNC210 program.
Formulated as an oral solid tablet BNC210 is a best-in-class negative allosteric modulator of the α7 nicotinic acetylcholine receptor under development for the treatment of SAD and Post-Traumatic Stress Disorder (PTSD). BNC210 has been given FDA Fast Track designation for acute treatment of SAD and other anxiety related disorders, and for treatment of PTSD and other trauma and stressor related disorders.
A live question and answer session will follow the formal presentations.